Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Head and neck cancer

2064 - Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-Positive Oropharyngeal Cancer (HPV+OPC)


30 Sep 2019


Proffered Paper – Head and neck cancer


David Jones


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


D.A. Jones1, H. Mehanna2, P. Mistry3, M. Dalby3, T. Fulton-Lieuw2, A.H. Kong2, J. Dunn3, A. Gray1

Author affiliations

  • 1 Nuffield Department Of Population Health, University of Oxford, OX3 7LF - Oxford/GB
  • 2 Institute Of Cancer And Genomic Sciences, University of Birmingham, B15 2TT - Birmingham/GB
  • 3 Warwick Clinical Trials Unit, University of Warwick, CV4 7AL - Warwick/GB


Login to access the resources on OncologyPRO.

Abstract 2064


Results from De-ESCALaTE HPV confirmed the dominance of cisplatin over cetuximab chemoradiotherapy for tumour control in patients with HPV+OPC. We report a comparison of QoL, resource use and healthcare costs in both arms, as well as updated 24 month survival and recurrence.


At various intervals from baseline to 24 months post treatment (PT), patient reported QoL and resource use were assessed through the EQ-5D-5L and a trial-specific resource use questionnaire supplemented by case report forms. Healthcare costs were estimated by applying UK-based unit cost to resource use items. Missing data were imputed. Differences in mean EQ-5D-5L utility index and adjusted cumulative QALYs were compared using the Wilcoxon signed-rank test and linear regression respectively. Mean resource usage and costs were compared though two-sample t-tests.


334 patients were randomised to cisplatin (n = 166) or cetuximab (n = 168). EQ-5D-5L utility index scores showed substantially lower mean QoL at the end of treatment for both study arms compared to baseline, before both recovering by 12 months PT. No significant differences between arms were detected at any time point. The difference in cumulative quality-adjusted survival, adjusted for baseline QoL, gender and comorbidities, widened over time and became significant at 6 months PT. By 24 months PT, mean difference was 0.107 QALYs in favour of cisplatin (95% CI: 0.029 to 0.186, p = 0.007), driven by the higher rate of mortality in the cetuximab arm. We found no statistically significant differences in the mean number or cost of hospital inpatient days, day case/outpatient visits, A&E visits, or primary/community care contacts. The cost of cetuximab-based chemoradiotherapy was, however, £7780 (P < 0.001) more expensive. Total costs at 24 months PT averaged £13517 (SE: £345) per patient for cisplatin and £21064 (SE: £400) for cetuximab. Treatment with cetuximab therefore significantly increased total cost per patient by £7547 (95% CI: £6512 to £8582).


When added to radiotherapy, cisplatin chemotherapy provided more QALYs and was less costly than cetuximab.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Hisham Mohamed Mehanna.


Cancer Research UK.


H. Mehanna: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Spouse / Financial dependant: Warwickshire Head and Neck Clinic; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi Pasteur; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck; Honoraria (self), Research grant / Funding (self): AstraZeneca; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Silence Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings